Third Rock Ventures
Executives
View the org chart displaying its 35 main executives
Most searched biographies at Third Rock Ventures
- Chris Robinson, Chief Talent Officer
- Abbie Celniker, Partner, Formation, Development and Strategy
- Neil Exter, Partner, Formation, Development and Strategy
Popular executive movements at Third Rock Ventures
- Courtney Wallace has joined the company as Venture Partner (posted on January 26 2024).
- Jigar Raythatha, who was Venture Partner, is promoted to Partner (posted on January 26 2024).
- Vyas Ramanan, who was Principal, is promoted to Venture Partner (posted on January 26 2024).
Click here to view some more movements at Third Rock Ventures
Create your alert
to follow the executive moves at Third Rock Ventures.
Fund
Third Rock Ventures has 1,473 competitors including Lloyds Development Capital (United Kingdom (UK)), BlackRock (United States (USA)) and WindRose Health Investors (United States (USA)).
Popular M&A news in Fund
- HMC Capital has acquired StratCap (posted on February 28 2024).
- Thomvest Ventures has just announced a $250 Million fundraising (posted on January 17 2024).
- BlackRock has announced the acquisition of Global Infrastructure Partners (posted on January 15 2024).
Popular contacts in Fund
- Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer at Valor Equity Partners
- Mortimer Buckley - Chairman of the Board and Chief Executive Officer (retiring in Dec 2024) at Vanguard
- Jean-Marc Arbaud - President and Chief Executive Officer of CDPQ Infra at Caisse de Dépôt et Placement du Québec
News
Press releases by Third Rock Ventures
- Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 | Tango Therapeutics, Inc
- Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis | Pliant Therapeutics, Inc.
- Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors - Septerna
- Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis | Pliant Therapeutics, Inc.
- CARGO Therapeutics Announces Pricing of Initial Public Offering | CARGO Therapeutics, Inc.
- Terremoto Biosciences Closes $175 Million Series B Financing | Terremoto
- Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
- Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023 | Pliant Therapeutics, Inc.
- Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer | Pliant Therapeutics, Inc.
- Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) | Fulcrum Therapeutics
- View more press releases Close
Social media about Third Rock Ventures
- Third Rock Ventures on Wikipedia, Google News & Yahoo Finance
- Third Rock Ventures on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Alison Connors 
Call Third Rock Ventures at +1 617...
